Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.

TitleRecovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.
Publication TypeJournal Article
Year of Publication2016
AuthorsBurns, LJ, Logan, BR, Chitphakdithai, P, Miller, JP, Drexler, R, Spellman, S, Switzer, GE, Wingard, JR, Anasetti, C, Confer, DL
Corporate AuthorsBlood and Marrow Transplant Clinical Trials Network
JournalBiol Blood Marrow Transplant
Volume22
Issue6
Pagination1108-1116
Date Published2016 06
ISSN1523-6536
KeywordsAdult, Blood Cell Count, Bone Marrow Transplantation, Convalescence, Fatigue, Female, Hemoglobins, Humans, Male, Middle Aged, Pain, Peripheral Blood Stem Cell Transplantation, Tissue and Organ Harvesting, Unrelated Donors, Young Adult
Abstract

We report a comparison of time to recovery, side effects, and change in blood counts from baseline to after donation from unrelated donors who participated in the Blood and Marrow Transplant Clinical Trials Network phase III randomized, multicenter trial (0201) in which donor-recipient pairs were randomized to either peripheral blood stem cell (PBSC) or bone marrow (BM) donation. Of the entire cohort, 262 donated PBSC and 264 donated BM; 372 (71%) donors were from domestic and 154 (29%) were from international centers (145 German and 9 Canadian). PBSC donors recovered in less time, with a median time to recovery of 1 week compared with 2.3 weeks for BM donors. The number of donors reporting full recovery was significantly greater for donors of PBSC than of BM at 1, 2, and 3 weeks and 3 months after donation. Multivariate analysis showed that PBSC donors were more likely to recover at any time after donation compared with BM donors (hazard ratio, 2.08; 95% confidence interval [CI], 1.73 to 2.50; P

DOI10.1016/j.bbmt.2016.02.018
Alternate JournalBiol Blood Marrow Transplant
PubMed ID27013014
PubMed Central IDPMC4867293
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
U10 HL108987 / HL / NHLBI NIH HHS / United States
U10 HL109137 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States